China Pharma Holdings Inc (CPHI) - Total Liabilities
Based on the latest financial reports, China Pharma Holdings Inc (CPHI) has total liabilities worth $7.49 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of China Pharma Holdings Inc to assess how effectively this company generates cash.
China Pharma Holdings Inc - Total Liabilities Trend (2001–2024)
This chart illustrates how China Pharma Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Check CPHI financial resilience to evaluate the company's liquid asset resilience ratio.
China Pharma Holdings Inc Competitors by Total Liabilities
The table below lists competitors of China Pharma Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Applied DNA Sciences, Inc.
NASDAQ:BNBX
|
USA | $2.24 Million |
|
Foresight Autonomous Holdings Ltd
TA:FRSX
|
Israel | ILA2.92 Million |
|
Thai Polycons Public Company Limited
BK:TPOLY
|
Thailand | ฿5.87 Billion |
|
ASA International Group PLC
LSE:ASAI
|
UK | GBX635.26 Million |
|
Pro-Pac Packaging Ltd
AU:PPG
|
Australia | AU$162.59 Million |
|
Femto Technologies Inc.
NASDAQ:FMTO
|
USA | $53.50 Million |
|
N. Leventeris S.A.
AT:LEBEK
|
Greece | €4.09 Million |
|
Tri Banyan Tirta Tbk
JK:ALTO
|
Indonesia | Rp641.88 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down China Pharma Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CPHI stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Pharma Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Pharma Holdings Inc (2001–2024)
The table below shows the annual total liabilities of China Pharma Holdings Inc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.14 Million | -20.80% |
| 2023-12-31 | $9.01 Million | -33.20% |
| 2022-12-31 | $13.49 Million | -18.87% |
| 2021-12-31 | $16.63 Million | +26.83% |
| 2020-12-31 | $13.11 Million | +0.89% |
| 2019-12-31 | $13.00 Million | -14.37% |
| 2018-12-31 | $15.18 Million | -10.09% |
| 2017-12-31 | $16.88 Million | -13.92% |
| 2016-12-31 | $19.61 Million | -20.22% |
| 2015-12-31 | $24.58 Million | -4.83% |
| 2014-12-31 | $25.83 Million | +4.71% |
| 2013-12-31 | $24.67 Million | +67.53% |
| 2012-12-31 | $14.72 Million | +5.86% |
| 2011-12-31 | $13.91 Million | +0.68% |
| 2010-12-31 | $13.81 Million | +31.00% |
| 2009-12-31 | $10.54 Million | +88.18% |
| 2008-12-31 | $5.60 Million | +42.05% |
| 2007-12-31 | $3.94 Million | -48.53% |
| 2006-12-31 | $7.66 Million | +11103.95% |
| 2005-12-31 | $68.41K | 0.00% |
| 2004-12-31 | $68.41K | -93.38% |
| 2003-12-31 | $1.03 Million | +4.09% |
| 2002-12-31 | $992.02K | 0.00% |
| 2001-12-31 | $992.02K | -- |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more